このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Median Technologies 将来の成長

Future 基準チェック /16

Median Technologiesは、3.4%と15.3%でそれぞれ年率3.4%で利益と収益が成長すると予測される一方、EPSはgrowで18.2%年率。

主要情報

0.4%

収益成長率

10.9%

EPS成長率

Healthcare Services 収益成長	25.8%
収益成長率	13.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	05 Sep 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:4ZG - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	34	-23	-24	-22	4
12/31/2025	27	-23	-23	-22	4
12/31/2024	23	-25	-22	-23	4
12/31/2023	23	-23	-22	-20	N/A
9/30/2023	23	-22	-20	-19	N/A
6/30/2023	23	-21	-19	-18	N/A
3/31/2023	23	-21	-18	-17	N/A
12/31/2022	24	-20	-17	-16	N/A
9/30/2022	24	-19	-16	-15	N/A
6/30/2022	23	-19	-15	-14	N/A
3/31/2022	22	-19	-13	-12	N/A
12/31/2021	21	-19	-11	-10	N/A
9/30/2021	19	-18	-10	-10	N/A
6/30/2021	18	-18	-10	-9	N/A
3/31/2021	16	-15	-8	-7	N/A
12/31/2020	14	-13	-6	-5	N/A
9/30/2020	12	-11	-4	-4	N/A
6/30/2020	11	-8	-3	-2	N/A
3/31/2020	10	-8	-4	-3	N/A
12/31/2019	9	-8	-5	-4	N/A
9/30/2019	8	-9	-8	-7	N/A
6/30/2019	7	-11	-11	-10	N/A
3/31/2019	7	-13	-13	-13	N/A
12/31/2018	6	-15	-16	-16	N/A
9/30/2018	7	-16	-17	-17	N/A
6/30/2018	7	-17	-18	-18	N/A
3/31/2018	7	-17	-16	-16	N/A
12/31/2017	8	-17	-14	-14	N/A
9/30/2017	8	-16	N/A	-12	N/A
6/30/2017	7	-14	N/A	-10	N/A
3/31/2017	7	-12	N/A	-9	N/A
12/31/2016	6	-9	N/A	-8	N/A
9/30/2016	6	-8	N/A	-6	N/A
6/30/2016	5	-7	N/A	-5	N/A
3/31/2016	5	-6	N/A	-4	N/A
12/31/2015	4	-6	N/A	-4	N/A
9/30/2015	3	-5	N/A	-4	N/A
6/30/2015	2	-5	N/A	-5	N/A
3/31/2015	2	-5	N/A	-4	N/A
12/31/2014	2	-4	N/A	-3	N/A
9/30/2014	1	-4	N/A	N/A	N/A
6/30/2014	1	-4	N/A	N/A	N/A
3/31/2014	1	-4	N/A	N/A	N/A
12/31/2013	1	-4	N/A	-4	N/A
9/30/2013	1	-4	N/A	N/A	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 4ZG今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 4ZG今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 4ZG今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 4ZGの収益 ( 15.3% ) German市場 ( 5.2% ) よりも速いペースで成長すると予測されています。

高い収益成長: 4ZGの収益 ( 15.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 4ZGの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Median Technologies 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2025

Recent updates

New minor risk - Market cap size

Median Technologies to Share Positive Pivotal Data for Eyonis LCS Diagnostic Software as Medical Device at the IASLC 2024 World Conference on Lung Cancer

Median Technologies Announces Pivotal Reality Study of Its Eyonis™? Lcs Lung Cancer Diagnostic Met All Primary and Secondary Endpoints

Median Technologies SA to Report First Half, 2024 Results on Oct 24, 2024

New major risk - Financial position

Median Technologies SA, Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: €1.25 loss per share (vs €1.28 loss in FY 2022)

New major risk - Share price stability

New minor risk - Share price stability

Median Technologies SA to Report Fiscal Year 2023 Results on Apr 25, 2024

Median Technologies's iBiopsy HCC Detection AI Model Developed on the PHELICAR Clinical Data Registry, to Be Presented at the ESMO Congress

Median Technologies Appoints Ben Mcdonald to Its Board of Directors

Median Technologies SA, Annual General Meeting, Oct 10, 2023

Median Technologies SA to Report First Half, 2023 Results on Oct 19, 2023

Median Technologies SA announced that it expects to receive €10 million in funding from Lake Bridge Capital Inc

Median Technologies SA announced that it expects to receive €10 million in funding from Lake Bridge Capital Inc

New major risk - Financial position

Median Technologies SA, Annual General Meeting, Jun 20, 2023

Full year 2022 earnings released: €1.28 loss per share (vs €1.25 loss in FY 2021)

Forecast to breakeven in 2025

Median Technologies SA to Report Fiscal Year 2022 Results on Apr 20, 2023

No independent directors

First half 2022 earnings released: €0.57 loss per share (vs €0.65 loss in 1H 2021)

Median Technologies Announces Formation of Clinical Advisory Board for Ibiopsy Lung Cancer Screening

Median Technologies SA to Report Q3, 2022 Results on Oct 20, 2022

Median Technologies SA Launches Imaging Lab, Spearheading the Integration of iBiopsy® Artificial Intelligence Technologies Into iCRO Imaging Services for Oncology Trials

Median Technologies SA, Annual General Meeting, Jun 14, 2022

No independent directors

Full year 2021 earnings released: €1.25 loss per share (vs €1.06 loss in FY 2020)

Median Technologies SA Files FDA 513(g) Regulatory Submission for iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device

Median Technologies Announces New Outstanding Performance for Its iBiopsy® Lung Cancer Screening CADx With a Focus on Stage 1 Lung Cancer Characterization

First half 2021 earnings released: €0.65 loss per share (vs €0.39 loss in 1H 2020)

Median Technologies SA announced that it has received €28.1 million in funding

Full year 2020 earnings released: €1.05 loss per share (vs €0.66 loss in FY 2019)

Median Technologies Appoints Thomas Bonnefont as Chief Operating and Commercial Officer

Median Technologies Sa Unveils New iBiopsy® Clinical Development Plan on Lung Cancer Screening

Median Technologies Inks Major Research Collaboration Agreement With the University of California San Diego

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘